The CTSA program is designed to strengthen and support the entire spectrum of translational research from scientific discovery to improved patient care.
Through a CTSA Program-supported KL2 Career Scholar Award, Dana Suskind, M.D., professor of surgery and pediatrics and director of the pediatric cochlear implant program at the University of Chicago Institute for Translational Medicine, leveraged her expertise and research background to establish the Thirty Million Words® Initiative. Through this effort, she and other researchers are developing and disseminating evidence-based, parent-directed programs to encourage early brain development. Her research continues to inform her scientific peers and the broader public, demonstrating the promise of the CTSA Program training investment.
- To help address challenges and get more treatments to more patients more quickly, NCATS announced new funding for 18 CTSA Program hubs. New awardees include the State University of New York at Buffalo and Wake Forest University Health Sciences.
- In response to the federal government's release of proposed changes to the Common Rule, which protects human subjects involved in research, CTSA Program representatives hosted a series of informational meetings to enhance understanding and facilitate public discussion about the proposed changes and their implications.
CTSA Program investigators made progress toward creating IRBrely, a national institutional review board (IRB) reliance agreement to streamline the review and approval of multisite clinical trials. The team is set to launch a pilot that will test components of IRBrely.
On Aug. 4, 2015, the White House announced that NIH is expanding its Innovation Corps (I-Corps™) training program to speed the commercialization of biomedical technologies developed with federal small business funding. The I-Corps "train-the-trainer" program will be offered to up to 10 institutions supported through the CTSA Program.
A Michigan research team funded in part by NCATS' CTSA Program and the National Heart, Lung, and Blood Institute has developed a life-saving diagnostic device that can test extremely small blood samples. The team is continuing development of the device and exploring commercial and regulatory pathways that could lead to approval for use in the clinic.
At the February 2015 CTSA Program principal investigators' meeting, researchers supported through the program provided updates about: